Company intelligence / Profile preview

Next Science

Sydney, New South Wales, Australiadownloads.regulations.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Next Science has developed and commercialized a proprietary non-toxic technology called XBIO that effectively eradicates both biofilm-based and free-floating bacteria. Their products have demonstrated efficacy in reducing surgical site and wound infections, with sustained effectiveness for up to five days in some applications. The company’s solutions are used to prevent infection by rinsing away debris/microorganisms or maintaining a moist environment conducive to healing.

Therapeutic areas: Infectious Diseases
Modalities: DeviceBiologicNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Next Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Next Science.

Explore the full profile